Nine Malaysian hospitals to work with WHO for drug trials on COVID-19

By Akshay Kedari  | Date: 2020-04-06

Nine Malaysian hospitals to work with WHO for drug trials on COVID-19

With the growing COVID-19 crisis, various initiatives are being taken worldwide where numerous organizations of various scale and are contributing as much as they can towards the efforts. The WHO, the biggest global authority responsible for international public health, is planning a solidarity trial to test various drugs that could help fight the coronavirus.

In a recent press release, the WHO, in collaboration with the Health Ministry of Malaysia, announced that the country has been selected to be a participant in the “Solidarity Trial”. Nine hospitals across Malaysia have been selected and would very soon initiate drug testing for coronavirus.   

Health Director-General, Datuk Dr. Noor Hisham Abdullah stated that the Health Ministry has expedited the process to conduct drug testing for the treatment of coronavirus patients. The trials would be conducted under the safety standards that are set by the National Pharmaceutical Regulatory Agency.

Dr. Noor further added that the participation of Malaysia in this global trial might help discover life-saving medicines to combat COVID-19 by evaluating their effectiveness and safety. Clinical Research Malaysia and Institute for Clinical Research of the Health Ministry of Malaysia would also help with the implementation of drug trials across the nation.

Queen Elizabeth Hospital, Sarawak General Hospital, Tengku Ampuan Afzan Hospital, Melaka Hospital, Kuala Lumpur Hospital, Sungai Buloh Hospital, Penang Hospital, Sultanah Bahiyah Hospital, and Tuanku Fauziah Hospital are the nine hospitals that have been selected from Malaysia to conduct trails of several drugs.       

Dr. Chow Ting Soo will lead the research and drug trials in Malaysia, and would also have access to a team of 16 Infectious Disease pharmacists and physicians working in their respective hospitals. Dr. Soo is an Infectious Disease Consultant in Penang Hospital.

The drug trials would primarily test the effectiveness of four different treatment protocols utilizing various combinations of five drugs which include Hydroxychloroquine, Chloroquine, Interferon beta, Lopinavir/Ritonavir, and Remdesivir.

Source credit: https://www.thestar.com.my/news/nation/2020/04/06/covid-19-nine-m039sian-hospitals-to-start-who-global-drug-trial

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

By Akshay Kedari

Following this funding, Interfor's long-term debt will hold a weighted average interest of 5.30% Interfor registered a Net Debt to the Invested Capital ratio of nearly 10% as of October 31, 2022 Interfor Corporation, one of the world...

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

By Akshay Kedari

Leading real estate services and investment company, ESR Group Limited, has recently announced that its exclusively-owned subsidiary, ARA and the Export-Import Bank of China have inked a breakthrough collaboration in a deal worth USD 1 billion infras...

Circularise nabs $11M to bring circular economy to industrial supply chains

Circularise nabs $11M to bring circular economy to industrial supply chains

By Akshay Kedari

Leading software platform, Circularise recently announced that it has raised $11.3 million (€11 million) in funding as part of its Series A round in a bid to advance its mission to bring a circular economy to industrial supply chains. The fun...

Sebi approves Adani Group’s proposal for additional 26% stake in NDTV

Sebi approves Adani Group’s proposal for additional 26% stake in NDTV

By Akshay Kedari

Adani Group, an Indian conglomerate, recently opened an offer to acquire an additional 26% share in New Delhi Television (NDTV), which was positively accepted by the Indian market regulator Sebi. The deal, worth USD 60.78 million, is expected to b...

ADB and Indonesia team up on coal power plant retirement contract

ADB and Indonesia team up on coal power plant retirement contract

By Akshay Kedari

The Asian Development Bank and Indonesia, along with a private power company announced partnering to refinance and retire a coal-fired power plant under a groundbreaking carbon emissions reduction program. According to reliable sources, West Java&...